Table 1.
Laboratory and clinical characteristics of study participants.
| Patients (n = 30) | Healthy individuals (n = 30) | P | |
|---|---|---|---|
| Laboratory data (admission) | |||
| Age* | 52.7 ± 12.3 | 50.3 ± 9.2 | 0.40 |
| Sex, male:female | 16:14 | 16:14 | 1.00 |
| Body mass index* | 30.6 ± 6.6 | 25.9 ± 4.2 | 0.006 |
| Hemoglobin, g/dL* | 13.96 ± 1.91 | 14.30 ± 1.11 | 0.42 |
| Leukocytes, ×109/L* | 8.04 ± 3.91 | 5.58 ± 1.58 | 0.004 |
| Neutrophils, ×109/L* | 6.38 ± 3.77 | 3.09 ± 0.93 | <0.001 |
| Lymphocytes, ×109/L* | 1.20 ± 0.55 | 1.79 ± 0.28 | <0.001 |
| Platelets, ×109/L* | 216.33 ± 93.02 | 245.59 ± 40.34 | 0.12 |
| NLR* | 6.19 ± 4.26 | 1.72 ± 0.61 | <0.001 |
| D-dimer, ng/mL* | 3.609 ± 14.440 | 324 ± 242 | <0.001 |
| C-reactive protein, mg/L* | 115.18 ± 75.74 | 4.15 ± 8.37 | <0.001 |
| Troponin, ng/mL* | 10.96 ± 11.98 | 4.33 ± 2.75 | <0.001 |
| CT score* | 17.8 ± 7.3 | NA | – |
| WHO-CPS score* (median and IQR) | 4919 (4103–6830) | NA | – |
| Outcome data | |||
| Time from symptom onset, days* | 8.1 ± 2.3 | NA | – |
| Length of hospital stay, days* | 12.9 ± 9.8 | NA | – |
| Need for intensive care (%)* | 12/30 (40%) | NA | – |
| Length of intensive care stay, days* | 6.1 ± 9.7 | NA | – |
NLR: neutrophil-to-lymphocyte ratio; NA: not applicable; WHO-CPS: World Health Organization’s Clinical Progression Scale; IQR: interquartile range.
*
Mean ± SD, WHO-CPS.